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During the 2003–04 influenza season, 17 cases of
Staphylococcus aureus community-acquired pneumonia
(CAP) were reported from 9 states; 15 (88%) were associ-
ated with methicillin-resistant S. aureus (MRSA). The medi-
an age of patients was 21 years; 5 (29%) had underlying
diseases, and 4 (24%) had risk factors for MRSA. Twelve
(71%) had laboratory evidence of influenza virus infection.
All but 1 patient, who died on arrival, were hospitalized.
Death occurred in 5 (4 with MRSA). S. aureus isolates were
available from 13 (76%) patients (11 MRSA). Toxin genes
were detected in all isolates; 11 (85%) had only genes for
Panton-Valentine leukocidin. All isolates had community-
associated pulsed-field gel electrophoresis patterns; all
MRSA isolates had the staphylococcal cassette chromo-
some mec type IVa. In communities with a high prevalence
of MRSA, empiric therapy of severe CAP during periods of
high influenza activity should include consideration for
MRSA. 
S
taphylococcus aureus is an infrequent cause of commu-
nity-acquired pneumonia (CAP), accounting for ≈3%
of cases in which a bacterial cause is identified, but it is a
recognized cause of influenza-associated CAP (1–4).
Methicillin-resistant S. aureus (MRSA) commonly causes
nosocomial pneumonia, but relatively few cases of MRSA
CAP have been reported (5,6). 
Recent reports have shown that MRSA is an emerging
cause of skin and soft tissue disease among otherwise
healthy persons who have little or no contact with health-
care settings (7,8). These community-associated strains of
MRSA differ from healthcare-associated strains by having
a characteristic methicillin-resistant gene cassette (staphy-
lococcal cassette chromosome mec [SCCmec] type IV)
that elicits certain toxins, notably Panton-Valentine leuko-
cidin (PVL), resistance generally limited to the β-lactams
and macrolides, and specific molecular typing patterns
(8–10). 
During the 2003–04 influenza season, the Centers for
Disease Control and Prevention (CDC) received reports of
severe complications after influenza virus infection,
including pneumonia caused by S. aureus and MRSA,
among previously healthy children and adults. We report
the demographic and clinical features of 17 patients with S.
aureus and MRSA CAP associated with influenza or
influenzalike illness (ILI) and describe the microbiologic
characteristics of the S. aureus isolates. 
Methods
Case Definition and Case Finding
A case of S. aureus CAP associated with ILI (S. aureus
CAP-ILI) was defined as pneumonia occurring during the
2003–04 influenza season in a person with either laborato-
ry-confirmed influenza virus infection, clinician-deter-
mined ILI (e.g., fever plus sore throat or cough), or both
during the 2003–04 influenza season from whom a speci-
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hours after hospitalization yielded S. aureus. Cases were
identified by following up on reports of influenza-associ-
ated staphylococcal complications on 2 influenza assess-
ment surveys conducted in December 2003 by the
Infectious Diseases Society of America Emerging
Infections Network, which consists of 859 infectious dis-
ease consultants (11). These surveys collected information
on the 2003–04 influenza outbreak, including influenza-
related complications, such as secondary bacterial infec-
tions, among pediatric and adult populations. Reports were
also received through state and local health departments.
Detailed clinical information on 4 cases was presented pre-
viously (12). We contacted clinicians and collected infor-
mation by using a standardized data collection form on
patient demographics, past medical history, signs and
symptoms at the time the patient sought medical care, hos-
pitalization, laboratory data including influenza testing,
and risk factors for acquisition of MRSA (i.e., hospitaliza-
tion, dialysis, surgery, or residence in a long-term care
facility in the previous year; ever having an MRSA infec-
tion; and presence of percutaneous device or catheter at
time of positive S. aureus culture). In addition, data on
empiric (i.e., before S. aureus culture results were known)
and targeted (i.e., after S. aureus culture results known)
antimicrobial therapy and clinical outcomes were collect-
ed. Discordant empiric or targeted therapy was defined as
a drug regimen that did not include an antimicrobial agent
to which S. aureus was susceptible.  
Laboratory Procedures
S. aureus isolates from patients were collected and sent
to CDC for characterization. All available isolates were
tested for susceptibility to chloramphenicol, clindamycin,
erythromycin, gentamicin, levofloxacin, linezolid,
oxacillin, penicillin, rifampin, tetracycline, trimethoprim-
sulfamethoxazole, and vancomycin by using broth
microdilution, as recommended by the Clinical Laboratory
Standards Institute (13). Inducible clindamycin resistance
was determined for isolates with the erythromycin-resist-
ant/clindamycin-susceptible phenotype by using the dou-
ble-disk diffusion test (D-zone test) (13). All isolates were
tested for genes encoding selected toxins (staphylococcal
enterotoxin [SE] A–E, H; PVL; and toxic shock syndrome
toxin 1) by multiplex real-time polymerase chain reaction
(PCR) using primers prepared at CDC. All MRSA isolates
underwent typing of their SCCmec gene cassette with PCR
(14). Genotyping of all isolates was performed by pulsed-
field gel electrophoresis (PFGE) with SmaI-digested DNA,
and gels were analyzed as previously described (9).
Results
Case Characteristics
From November 10, 2003, to January 4, 2004, 17 cases
of  S. aureus CAP-ILI were reported from 9 states
(Alabama, Arkansas, Illinois, Maryland, Michigan,
Missouri, Oklahoma, Texas, and Washington); 15 (88%)
were due to MRSA. The median age of the 17 case-
patients was 21 years; 5 (29%) patients had underlying dis-
eases, and 4 (24%) had risk factors for MRSA (Table 1)
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groups (i.e., underlying illness [n = 2], age 50–64 years [n
= 3]) recommended for annual influenza vaccination under
current guidelines, only 1 (20%) had documented influen-
za vaccination during 2003–04. All case-patients had clini-
cian-determined ILI. Twelve (71%) of the 17 patients had
laboratory-confirmed influenza virus infection; 10 of these
were confirmed by rapid antigen testing. S. aureus was
recovered from multiple sources including sputum (14
[82%]), blood (8 [47%]), and pleural fluid (4 [24%].
Respiratory symptoms began a median of 4 days (range
1–17 days) before S. aureus specimen collection. All
patients had >1of the following at the time they sought
medical care: cough, myalgias, sore throat, headache, or
shortness of breath. Most had fever, hypotension, and nor-
mal or elevated leukocyte counts. Four (25%) had leukope-
nia, and 6 (38%) had thrombocytopenia. Radiologic
information was available for review for 16 patients, and
all had documentation of an infiltrate. Information on
empiric antimicrobial therapy was available for 15
patients; most received a third-generation cephalosporin (9
[60%]), respiratory fluoroquinolone (i.e., levofloxacin, gat-
ifloxacin, or moxifloxacin) (7 [47%]), or vancomycin (10
[67%]); most patients (13 [87%]) received multiple antimi-
crobial agents. Discordant empiric antimicrobial therapy
was documented in 3 (20%) patients, all of whom received
a third-generation cephalosporin with or without a
macrolide. Information on targeted antimicrobial therapy
was provided for 13 patients (2 died before targeted treat-
ment could be initiated) and consisted of vancomycin (10
[77%]), linezolid (2 [15%]), clindamycin (5 [38%]), and
fluoroquinolones (4 [31%]); many patients (9 [69%])
received multiple antimicrobial drugs. 
One patient was pronounced dead on arrival at the
emergency department. Most patients were admitted to the
intensive care unit and required intubation, and placement
of chest tubes (Table 2). The median number of hospital
days for patients was 13 (range 1–108 days). Five patients
(4 with MRSA) died; their median age was 28 years (range
2 months–52 years), and only 1 had underlying illness
(diabetes). Most died within 1 week of symptom onset.
Laboratory Findings
S. aureus isolates were available from 13 (76%) patients
(11 MRSA, 2 methicillin-susceptible S. aureus) from 9
states. Toxin genes were detected in all isolates; 11 (85%)
had only the PVL genes, whereas 2 (15%) had genes for
SEA, SEB, and SEH (Figure) All MRSA isolates had the
SCCmec type IVa resistance gene cassette. Antimicrobial
drug–susceptibility testing results for the MRSA isolates
showed that all were resistant to oxacillin and erythromycin
but susceptible to linezolid, rifampin, trimethoprim-sul-
famethoxazole, and vancomycin; 10 (91%) and 6 (55%)
isolates, respectively, were susceptible to clindamycin and
levofloxacin. The 1 MRSA isolate that was not susceptible
to clindamycin demonstrated inducible resistance by the D-
zone test. In 4 cases, isolates were not available for testing
at CDC. Antimicrobial drug susceptibility test results per-
formed at the treating facility indicated that these 4 isolates
were MRSAand nonsusceptible to macrolides (n = 4), clin-
damycin (n = 1), and levofloxacin (n = 1).
Analysis of PFGE results showed that 11 (85%) were
community-associated pulsed-field types USA300, and 2
(15%) were USA400, according to CDC criteria (Figure).
Of the 10 MRSA isolates that were classified as pulsed-
field type USA300, 8 (80%) from 6 different states had
indistinguishable banding patterns and were further classi-
fied as USA300 subtype 0114. These MRSA isolates dif-
fered from pulsed-field types associated with healthcare-
related strains (USA100 and 200) (9).
Discussion
We report the emergence of S. aureus and MRSA as a
cause of CAP-ILI resulting in severe illness and death in
otherwise healthy persons in the United States during the
2003–04 influenza season. Most infections were caused by
MRSA strains that contained PVL genes and were uni-
formly resistant to macrolides; half were nonsusceptible to
fluoroquinolones. However, the isolates were susceptible
to other antimicrobial agents, including vancomycin and
linezolid. Although some phenotypic differences were
noted, most cases of pneumonia appeared to be attributa-
ble to a single strain of MRSA found in diverse geograph-
ic areas. This strain, USA300 subtype 0114, is a
predominant strain responsible for community outbreaks
of MRSA skin disease in the United States (8,9,15). 
Postinfluenza staphylococcal pneumonia has been
reported in healthy adults during influenza pandemics and
epidemics for the last century; it has been reported in the
literature less frequently during the past 30 years (1–3).
The recognition of MRSA as a cause of CAP-ILI has
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ingly common cause of skin and soft tissue infection in the
community. Molecular typing of isolates in our series
demonstrates that the CAP-ILI isolates are indistinguish-
able from MRSA associated with numerous outbreaks of
skin and soft tissue infections (8). Given this association,
MRSA might become a more common cause of S. aureus
CAP following or coincident to influenza infection in
regions where the MRSA strain is prevalent as a cause of
skin and soft tissue infection. Antecedent S. aureus skin
infection or colonization may be associated with postin-
fluenza S. aureus CAP, as was reported during the 1957
influenza pandemic (16). Although we did not systemati-
cally collect information on antecedent skin infections in
our study, skin infections occurring among families of
case-patients were noted. Given the apparent wide nation-
al distribution of MRSA as a cause of skin disease, physi-
cians should be aware that MRSA can cause not only skin
and soft tissue infections but also CAP. 
Although most of the reported patients had laboratory
confirmation of influenza virus as a cause of preceding ill-
ness, those diagnoses based solely on clinical symptoms
may have been caused by other viral respiratory
pathogens. However, growing evidence of mechanisms by
which influenza may interact specifically with S. aureus to
increase the risk for influenza–S. aureus co-infections sug-
gests that these S. aureus CAP infections were likely asso-
ciated with influenza (17). These include an influenza-
induced increase in S. aureus–specific adhesion through-
out the respiratory tract and S. aureus–specific proteases,
which may increase influenza viral replication (18–20).
This latter mechanism actually points to a synergistic rela-
tionship in which S. aureus increases influenza disease
severity while influenza increases S. aureus infection and
severity. Strains of influenza A virus also decrease phago-
cytic killing of S. aureus, leading to increased host suscep-
tibility to bacterial superinfection (21). No other respirato-
ry virus appears to share with influenza such a prominent
role in predisposing to and increasing the severity of S.
aureus pneumonia.
Risk factors for postinfluenza S. aureus CAP are unde-
fined, but annual influenza vaccination is not recommend-
ed for half of the patients reported in our series under
current guidelines (22). However, influenza vaccination is
a major preventive strategy for influenza-associated pneu-
monia in older adults and in children 6–23 months of age
(22,23). Moreover, studies have demonstrated that influen-
za vaccination can decrease the incidence of upper respira-
tory infections and lessen the need for antimicrobial drug
use in healthy adults (24,25). Although these studies do not
focus on specific bacterial complications, many studies
have shown that influenza vaccination reduces overall
pneumonia risk; thus one can reasonably assume that
influenza vaccination would prevent secondary bacterial
infections, including MRSA, in immunocompetent adults
(24,26). Because information on antiviral treatment was
not collected and most patients in this series sought med-
ical care >2 days after illness onset, we could not assess
the effects of early antiviral treatment. Although 1 study
reported that early antiviral treatment of influenza with
oseltamivir can decrease the incidence of lower respirato-
ry tract complications, further studies are needed to deter-
mine whether early antiviral treatment of influenza can
help reduce the risk for S. aureus pneumonia associated
with influenza (22,27). 
The incidence of MRSA CAP is unknown. In 2004, to
monitor the incidence of MRSA, CDC initiated active pop-
ulation-based surveillance for invasive MRSAdisease in 9
locations in the United States through the Emerging
Infections Programs, Active Bacterial Core surveillance.
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Figure. Dendrogram of Staphylococcus aureus isolates determined by using SmaI–digested DNA recovered from patients with commu-
nity-acquired pneumonia associated with influenzalike illness, influenza season, 2003-04. NA, not applicable (methicillin-susceptible);
SE, staphylococcal enterotoxin A, B, C, H; REF, reference strain; PVL, Panton-Valentine leukocidin; TSST, toxin shock syndrome toxin;
CHL, chloramphenicol; CLI, clindamycin; ERY, erythromycin; GM, gentamicin; LEV, levofloxacin; OX, oxacillin; PEN, penicillin; TET, tetra-
cycline. *Inducible clindamycin resistance. These data will help characterize the further emergence of
MRSA as a cause of CAP, guide public health interven-
tions to prevent these infections, and provide information
to guide empiric therapy recommendations. Currently rec-
ommended empiric therapy of CAP in immunocompetent
adults with bacterial superinfection following influenza
consists of a β-lactam or respiratory fluoroquinolone and
may not adequately provide activity against community
strains of MRSA (28). Whenever possible, physicians
should obtain specimens (e.g., sputum or blood cultures)
for diagnostic and antimicrobial drug–susceptibility test-
ing to target therapy (28,29). Most patients in our series
had severe disease and received broad-spectrum antimi-
crobial drugs, including coverage for resistant gram-posi-
tive bacteria. Whether initial inadequate empiric therapy
plays a role in patient outcomes is therefore unknown.
Our cases suggest that empiric therapy of severe CAP
during periods of high influenza activity should include
coverage for MRSA, including among those without rec-
ognized risk factors for MRSA. In this regard, our con-
cerns echo those of Martin et al. in 1959. Following these
researchers’ experience with the emergence of penicillin-
resistant staphylococci during the 1957–58 Asian influen-
za pandemic, they commented “…during epidemics of
influenza in localities in which staphylococci are known to
be prevalent, all patients with signs of severe, potentially
fatal influenza should—until proven otherwise—be diag-
nosed and treated promptly as cases of staphylococcal
pneumonia caused by relatively antibiotic-resistant staphy-
lococci” (1). 
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